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arning! Context-Sensitive Data*
oger M. Mills, MD, FACC
etroit, Michigan
or 300 years, from the time of William Harvey and
tephan Hales (1) until Braunwald, Ross, and Sonnenblick
2), physicians and investigators focused their attention on
he pumping function of the heart with great success.
uring the past 50 years, however, a steadily growing body
f evidence has awakened us to another critical role of the
eart in the homeostasis of the milieu interieur, the regu-
ation of salt and water balance.
See page 533
Cardiovascular participation in the regulation of salt and
ater balance occurs through at least two different physio-
ogically reciprocal mechanisms, one to retain and one to
ose salt and water. The first includes cardiac participation
n well-described complex neural-vascular feedback loops
nvolved in the regulation of renin-angiotensin secretion
nd sympathetic nervous system activity, recognized as
ritical components in the clinical pathophysiology of heart
ailure (3). The second mechanism, cardiac synthesis of
asoactive natriuretic peptides, has now captured the inter-
st and imagination of clinical researchers. In the family of
atriuretic peptides, the B-type natriuretic peptide (BNP)
ystem offers relative stability and ease of assay and recently
as become a favorite target for clinical investigators.
ardiac myocytes synthesize the 108 amino-acid parent
eptide, proBNP, “on demand” with minimal, if any,
ntracellular storage. The proBNP is cleaved to produce two
table molecules, the physiologically active 32 amino-acid
eptide BNP and inactive N-terminal pro-B-type natri-
retic peptide (NT-proBNP). B-type natriuretic peptide is
leared from the circulation with a half-life of approximately
8 min, primarily by endothelial natriuretic peptide A-
eceptors; membrane-bound endopeptidase also plays a role
n clearance (4–6). The NT-proBNP fragment is cleared
rimarily by the kidney. Its half-life in humans is not
nown, but in sheep, the half-life of NT-proBNP is
ubstantially longer than that of BNP (6).
Because of differences in their metabolic fate, BNP and
T-proBNP levels are not necessarily clinically inter-
hangeable. Widely available commercial assays have facil-
tated clinical studies of both the active moiety, BNP, and
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
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ospital, Detroit, Michigan. Dr. Mills has received research support and honoraria
rom Scios Inc.he inactive fragment, NT-proBNP. To date, clinical stud-
es have clearly documented the utility of BNP levels in
acilitating the diagnostic evaluation of patients complain-
ng of acute dyspnea (7,8). Additional data also suggest that
ncreased levels of BNP have prognostic importance in the
etting of acute ischemic events (9–11). These studies have
ooked at two fundamentally different problems. The first
nvolves the response of BNP to abnormal ventricular
oading and acute diagnosis; the second involves the eleva-
ion of BNP associated with myocardial ischemia and
ong-term prognostic assessment.
In this issue of the Journal, Lindahl et al. (12) present a
ubstantial addition to the existing data on the prognostic
mportance of NT-proBNP levels during and after non–
T-segment elevation acute coronary syndromes. They
eport observations in 1,352 of the 3,489 patients enrolled in
he Fragmin and fast Revascularization during InStability in
oronary artery disease (FRISC-II) trial, a randomized trial
f early invasive versus noninvasive management and three
onths subsequent treatment with dalteparin versus pla-
ebo. They measured NT-proBNP levels at randomization,
hich was a median of 38 h after onset of the most recent
ymptoms, then at 48 h, 6 weeks, 3 months, and 6 months
fter randomization. Initially, NT-proBNP levels were
arkedly elevated. A rapid early decline was followed by a
rolonged slow decrease during the ensuing six months. At
ach time point, the subjects with elevated NT-proBNP
evels had a greater risk of subsequent death, but “the
bsolute levels of NT-proBNP associated with a certain
pecificity are vastly different in stable and unstable phases.”
or example, “an NT-proBNP level 264 ng/l at six
onths had the same specificity for subsequent death as a
evel above 722 ng/l at randomization.” In their discussion,
he authors hypothesize that the acute phase NT-proBNP
levations reflected myocardial damage, perhaps associated
ith microembolization. In contrast, persistent elevation of
T-proBNP levels at three to six months after the acute
vent was associated with chronically impaired left ventric-
lar function.
These data have important implications for both clini-
ians and investigators. We clinicians have another carefully
erformed clinical trial confirming the prognostic impor-
ance of elevated levels of BNP in the setting of acute
oronary syndromes. Given the potential benefits of inter-
ention for high-risk patients set against the risk and
xpense that accrue to low-risk individuals, honing our
bility to discriminate these subsets of patients is increas-
ngly important to cost-effective and evidence-based man-
gement. The well-documented observation that the abso-
ute NT-proBNP level associated with a given risk falls with
ime (or, conversely, that the risk associated with a given
NP level rises with time) once again highlights the critical
mportance of interpreting laboratory data in clinical con-
ext. From a practical viewpoint, patients with persistently
levated NT-proBNP levels at three months after acute
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February 15, 2005:542–3 Editorial Commentoronary syndrome should undergo careful re-evaluation for
nterventions to reduce long-term risk. Unfortunately, the
RISC-II study data do not include information on the
mpact of angiotensin-converting enzyme inhibitors and
eta-blockers on NT-proBNP in these subjects.
For investigators, these data raise a number of questions.
s the authors point out, the substantial elevations of BNP
evels associated with acute coronary syndromes cannot be
xplained by the mechanical stimulus of reduced global left
entricular function. The acute coronary syndrome must
nclude a stimulus for de novo synthesis of the natriuretic
eptides. Lindahl et al. (12) speculate that interleukin-6
ay play a role in this process, but they offer no direct
vidence to support this assertion. In fact, the signal
ransduction involved in regulating the physiologic and
athophysiologic production of the natriuretic peptides at
he molecular level remains something of a mystery. Goetz
4) has recently reviewed BNP expression in ischemic heart
isease. The available data suggest that multiple processes
mpact BNP levels, including both chronic hemodynamic
oading and acute ischemia. (Fig. 1) These insights may help
o explain a number of previously puzzling findings, includ-
igure 1. Proposed stimuli for secretion of B-type natriuretic peptide
BNP). mRNA  messenger ribonucleic acid. Reprinted from Goetz JP.
ro-BNP-derived peptides in cardiac disease. Scand J Clin Lab Invest
004;6:497–510, by permission of Taylor & Francis AS.ng substantial rises in BNP levels after cardiac surgery.nraveling the physiology of the natriuretic peptides re-
ains a challenge.
Certainly, we have more data and more tools than
arvey, and we live in a more complex world. However, it
s unlikely that any of us are inherently brighter or more
stute thinkers than he, or more articulate than his fellow
lizabethan Englishman, William Shakespeare. Looking at
hese data reinforce the importance of context, as Hamlet so
uccinctly told Rosencrantz and Guildenstern, “for there is
othing either good or bad but thinking makes it so” (The
ragedy of Hamlet, Prince of Denmark, Act II, Scene 2).
eprint requests and correspondence: Dr. Roger M. Mills,
eart Failure Section, Division of Cardiovascular Medicine,
enry Ford Hospital, 2799 West Grand Boulevard, Detroit,
ichigan 48202-2689. E-mail: rmills1@hfhs.org.
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